The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending the combination of ivosidenib and azacitidine for people diagnosed with acute myeloid ...

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...

Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

Olutasidenib shows sustained efficacy and manageable safety in relapsed/refractory mutant IDH1 acute myeloid leukemia, with a 35% complete remission rate and 48% overall response rate. Patients with ...